Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

Study of Dextromethorphan in OCD and Related Disorders

Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD) - Living within California - Capacity to provide willing to sign a consent form Who Should NOT Join This Trial: - Current bipolar disorder or psychotic disorder - Active moderate or severe substance use disorder, lifetime severe substance use disorder - Pregnant or nursing women - Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start - Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD) * Living within California * Capacity to provide informed consent Exclusion Criteria: * Current bipolar disorder or psychotic disorder * Active moderate or severe substance use disorder, lifetime severe substance use disorder * Pregnant or nursing women * Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start * Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

Treatments Being Tested

DRUG

Fluoxetine

Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks

DRUG

Dextromethorphan

Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.

Locations (1)

Stanford University
Stanford, California, United States